Biofrontera, Inc. (BFRI)
0.7891
+0.01
(+1.04%)
USD |
NASDAQ |
Oct 23, 16:00
0.7801
-0.01
(-1.14%)
After-Hours: 20:00
Biofrontera EPS Diluted (Quarterly) : -0.0467 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0467 |
| March 31, 2026 | -0.4067 |
| December 31, 2025 | 0.4842 |
| September 30, 2025 | -0.617 |
| June 30, 2025 | -0.5693 |
| March 31, 2025 | -0.4736 |
| December 31, 2024 | -0.1573 |
| September 30, 2024 | -0.9818 |
| June 30, 2024 | -0.0505 |
| March 31, 2024 | -2.880 |
| December 31, 2023 | 1.647 |
| September 30, 2023 | -4.640 |
| June 30, 2023 | -7.229 |
| Date | Value |
|---|---|
| March 31, 2023 | -5.602 |
| December 31, 2022 | -2.086 |
| September 30, 2022 | -2.258 |
| June 30, 2022 | -0.9032 |
| March 31, 2022 | 6.491 |
| December 31, 2021 | -16.96 |
| September 30, 2021 | -27.61 |
| June 30, 2021 | -6.312 |
| March 31, 2021 | -6.093 |
| September 30, 2020 | -5.147 |
| June 30, 2020 | -6.40 |
| March 31, 2020 | -7.076 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 0.0858 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.604M |
| Revenue (Quarterly) | 12.00M |
| Total Expenses (Quarterly) | 12.61M |
| Enterprise Value | 14.05M |
| Gross Profit Margin (Quarterly) | 91.59% |
| Profit Margin (Quarterly) | -5.03% |
| Earnings Yield | -74.29% |
| Normalized Earnings Yield | -35.80 |